KR100615757B1 - 에스트로겐 수용체를 조절하는 화합물 및 방법 - Google Patents

에스트로겐 수용체를 조절하는 화합물 및 방법 Download PDF

Info

Publication number
KR100615757B1
KR100615757B1 KR1020017008410A KR20017008410A KR100615757B1 KR 100615757 B1 KR100615757 B1 KR 100615757B1 KR 1020017008410 A KR1020017008410 A KR 1020017008410A KR 20017008410 A KR20017008410 A KR 20017008410A KR 100615757 B1 KR100615757 B1 KR 100615757B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
bone
cancer
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017008410A
Other languages
English (en)
Korean (ko)
Other versions
KR20010101346A (ko
Inventor
베른드엠. 스테인
데이비드더블유. 앤더슨
레아엠. 가요
메이에스. 수테르랜드
메리 더블데이
그라지엘라아이. 쉐블린
아담 코이스
사크 캄뭉쿠네
라비쿠마르 잘루리
쉬리파드에스. 바그와트
제프리에이. 미키
Original Assignee
시그날 파마소티칼 아이엔씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그날 파마소티칼 아이엔씨 filed Critical 시그날 파마소티칼 아이엔씨
Publication of KR20010101346A publication Critical patent/KR20010101346A/ko
Application granted granted Critical
Publication of KR100615757B1 publication Critical patent/KR100615757B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020017008410A 1998-12-30 1999-12-30 에스트로겐 수용체를 조절하는 화합물 및 방법 Expired - Fee Related KR100615757B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11447298P 1998-12-30 1998-12-30
US60/114,472 1998-12-30

Publications (2)

Publication Number Publication Date
KR20010101346A KR20010101346A (ko) 2001-11-14
KR100615757B1 true KR100615757B1 (ko) 2006-08-25

Family

ID=22355427

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017008410A Expired - Fee Related KR100615757B1 (ko) 1998-12-30 1999-12-30 에스트로겐 수용체를 조절하는 화합물 및 방법

Country Status (14)

Country Link
EP (1) EP1140889B1 (https=)
JP (1) JP2002533456A (https=)
KR (1) KR100615757B1 (https=)
CN (2) CN100339374C (https=)
AT (1) ATE248157T1 (https=)
AU (1) AU765159B2 (https=)
CA (1) CA2356986A1 (https=)
DE (1) DE69910830T2 (https=)
DK (1) DK1140889T3 (https=)
ES (1) ES2207982T3 (https=)
HK (1) HK1041258B (https=)
IL (2) IL144003A0 (https=)
PT (1) PT1140889E (https=)
WO (1) WO2000039120A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822563B2 (en) 1997-09-22 2004-11-23 Donnelly Corporation Vehicle imaging system with accessory control
US5877897A (en) 1993-02-26 1999-03-02 Donnelly Corporation Automatic rearview mirror, vehicle lighting control and vehicle interior monitoring system using a photosensor array
US7655894B2 (en) 1996-03-25 2010-02-02 Donnelly Corporation Vehicular image sensing system
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) * 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
PT1246814E (pt) * 1999-12-30 2005-07-29 Signal Pharm Llc Compostos e metodos para a modulacao de receptores de estrgenio
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
EP1281710A1 (en) * 2001-08-03 2003-02-05 CHIESI FARMACEUTICI S.p.A. 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
SK287086B6 (sk) * 2001-01-24 2009-11-05 Chiesi Farmaceutici S.P.A. 2H-1-Benzopyránové deriváty, farmaceutické prostriedky s ich obsahom a ich použitie
ES2236056T3 (es) * 2001-01-24 2005-07-16 Chiesi Farmaceutici S.P.A. Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
KR100715927B1 (ko) * 2001-04-10 2007-05-08 다카라 바이오 가부시키가이샤 치료제
US7148252B2 (en) * 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
EP1497277A1 (en) * 2002-04-19 2005-01-19 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
AU2003225228A1 (en) 2002-05-03 2003-11-17 Donnelly Corporation Object detection system for vehicle
US7091235B2 (en) 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
FR2849653B1 (fr) * 2003-01-08 2006-08-25 B F B Etudes Et Rech S Experim Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant
CA2538874A1 (en) * 2003-09-15 2005-03-31 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods of treatment therewith
US7526103B2 (en) 2004-04-15 2009-04-28 Donnelly Corporation Imaging system for vehicle
CA2595477A1 (en) * 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
EP1899316A1 (en) * 2005-06-24 2008-03-19 Signal Pharmaceuticals LLC Benzopyranone compounds for treating cancer
AR059339A1 (es) * 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
EP1860104A1 (en) * 2006-05-22 2007-11-28 Aptanomics Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof
CN101200460B (zh) * 2007-11-19 2010-06-16 北京珅奥基医药科技有限公司 二氢苯并吡喃酮类化合物及其用途
CN105541810B (zh) * 2016-03-04 2019-05-17 南京工业大学 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用
CN105801544A (zh) * 2016-04-18 2016-07-27 中国药科大学 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN105801543B (zh) * 2016-04-18 2019-08-02 中国药科大学 4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN112426420B (zh) * 2020-12-01 2021-12-28 浙江大学 香豆素-二硫代氨基甲酸酯衍生物在制备抗肿瘤药物中的应用
CN112645922B (zh) * 2020-12-24 2022-01-07 中国人民解放军空军军医大学 香豆素类化合物、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857401A (en) * 1956-12-20 1958-10-21 Searle & Co Acetylated coumarin derivatives
DE4323409A1 (de) * 1993-07-13 1995-01-19 Boehringer Mannheim Gmbh Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel
HUP9801829A3 (en) * 1995-02-06 1999-10-28 Lilly Co Eli Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6
CA2270111A1 (en) * 1996-10-28 1998-05-07 Lise Brown Christiansen Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU744403B2 (en) * 1996-10-28 2002-02-21 Novo Nordisk A/S Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
CA2270113A1 (en) * 1996-10-28 1998-05-07 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129627A0 (en) * 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA979644B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
WO1998018776A1 (en) * 1996-10-28 1998-05-07 Novo Nordisk A/S Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
논문 Contraception(Vol.35, no.3, 페이지 283-287, 1987 *

Also Published As

Publication number Publication date
IL144003A (en) 2006-07-05
DK1140889T3 (da) 2003-12-22
HK1041258A1 (en) 2002-07-05
WO2000039120A2 (en) 2000-07-06
DE69910830T2 (de) 2004-06-17
EP1140889A2 (en) 2001-10-10
IL144003A0 (en) 2002-04-21
EP1140889B1 (en) 2003-08-27
HK1041258B (en) 2003-12-12
ATE248157T1 (de) 2003-09-15
CN1597677A (zh) 2005-03-23
DE69910830D1 (de) 2003-10-02
PT1140889E (pt) 2004-01-30
CN1337958A (zh) 2002-02-27
CN1155589C (zh) 2004-06-30
AU2597000A (en) 2000-07-31
CA2356986A1 (en) 2000-07-06
WO2000039120A3 (en) 2000-10-26
AU765159B2 (en) 2003-09-11
HK1075893A1 (zh) 2005-12-30
JP2002533456A (ja) 2002-10-08
KR20010101346A (ko) 2001-11-14
ES2207982T3 (es) 2004-06-01
CN100339374C (zh) 2007-09-26

Similar Documents

Publication Publication Date Title
KR100615757B1 (ko) 에스트로겐 수용체를 조절하는 화합물 및 방법
US6331562B1 (en) Compounds and methods for modulation of estrogen receptors
US6372739B1 (en) Compounds and methods for modulation of estrogen receptors
EP1246814B1 (en) Compounds and methods for modulation of estrogen receptors
US6620838B1 (en) Benzopyrazone compounds, compositions thereof, and methods of treatment therewith
JP2007505835A (ja) ベンゾピラノン化合物、その組成物及びそれを用いた治療方法
CN100436440C (zh) 苯并吡喃酮化合物、其组合物以及其治疗方法
HK1075893B (en) Compounds and methods for modulation of estrogen receptors
HK1081957B (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090818

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090818

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000